Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)

Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista española de quimioterapia 2023-08, Vol.36 (4), p.400-407
Hauptverfasser: Risco-Risco, C, Martínez-Urbistondo, D, Suárez Del Villar, R, Ayerbe García-Monzón, L, Pérez-Rubio, A, Barberán-López, J, Andaluz-Ojeda, D, Villares Fernández, P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 407
container_issue 4
container_start_page 400
container_title Revista española de quimioterapia
container_volume 36
creator Risco-Risco, C
Martínez-Urbistondo, D
Suárez Del Villar, R
Ayerbe García-Monzón, L
Pérez-Rubio, A
Barberán-López, J
Andaluz-Ojeda, D
Villares Fernández, P
description Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs). Prospective post-authorization cohort study to monitor safety and effectiveness of the vaccine. Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic side effects were more frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 infection was associated with systemic effects after the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were reported. According to multivariate analysis, the degree of self-reported functional limitation after the first dose increased with age, female sex, previous COVID-19 contact, previous SARS-CoV-2 infection, and Charlson Comorbidity Index (CCI). After the second dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the degree of functional limitation after the first dose. Systemic adverse effects were more frequent after the second dose of Comirnaty. Previous SARS-CoV-2 infection was associated with systemic effects after the first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comirnaty®. After the 2nd dose, the degree of functional limitation was lower in those who previously had SARS-CoV-2 infection.
doi_str_mv 10.37201/req/017.2023
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10336310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2807918732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-90813d1d4d3273d39c17036d112b8c4a238c38dc392016fe9166c03f95938fd33</originalsourceid><addsrcrecordid>eNpVkc9u1DAQxi0EosvCkSvysRzS2p40sU-oivizUqUegF4t13Y2hsRObWfRvhS8A0-Gd1squMxoPD9938gfQq8pOYOWEXoe7d05oe0ZIwyeoBUVnFfigvKnaEUYrSuomThBL1L6RkgNtaDP0Qm0lAoKZIV-bXw_LtZri0OP7eyMnVwYw9ZpNWLlDdaj88ehVzqHmLDzOA8WR3uYt7YsXd7jHHAXJhe9yvvfP_FOae28PcCDVWMesFbR4h8hfrdFo3gp_HlW3qUBL97tyuNRpYgOzm_xENLscnE97a5vNjeXHU55Mfu3L9GzXo3Jvnroa_T1w_sv3afq6vrjpru8qjTUda4E4RQMNbUB1oIBoWlLoDGUsluua8WAa-BGgyhf2PRW0KbRBHpxIYD3BmCN3t3rzsvtZI22Pkc1yjm6ScW9DMrJ_zfeDXIbdpISgAZKXaPTB4UY7habspxc0nYclbdhSZJx0grKW2AFre5RHUNK0faPPpTIY8qypCxLyvKQcuHf_HvcI_03VvgD9SmnPw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2807918732</pqid></control><display><type>article</type><title>Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Risco-Risco, C ; Martínez-Urbistondo, D ; Suárez Del Villar, R ; Ayerbe García-Monzón, L ; Pérez-Rubio, A ; Barberán-López, J ; Andaluz-Ojeda, D ; Villares Fernández, P</creator><creatorcontrib>Risco-Risco, C ; Martínez-Urbistondo, D ; Suárez Del Villar, R ; Ayerbe García-Monzón, L ; Pérez-Rubio, A ; Barberán-López, J ; Andaluz-Ojeda, D ; Villares Fernández, P</creatorcontrib><description>Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs). Prospective post-authorization cohort study to monitor safety and effectiveness of the vaccine. Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic side effects were more frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 infection was associated with systemic effects after the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were reported. According to multivariate analysis, the degree of self-reported functional limitation after the first dose increased with age, female sex, previous COVID-19 contact, previous SARS-CoV-2 infection, and Charlson Comorbidity Index (CCI). After the second dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the degree of functional limitation after the first dose. Systemic adverse effects were more frequent after the second dose of Comirnaty. Previous SARS-CoV-2 infection was associated with systemic effects after the first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comirnaty®. After the 2nd dose, the degree of functional limitation was lower in those who previously had SARS-CoV-2 infection.</description><identifier>ISSN: 0214-3429</identifier><identifier>EISSN: 1988-9518</identifier><identifier>DOI: 10.37201/req/017.2023</identifier><identifier>PMID: 37119130</identifier><language>eng</language><publisher>Spain: Sociedad Española de Quimioterapia</publisher><subject>BNT162 Vaccine ; Cohort Studies ; COVID-19 - epidemiology ; COVID-19 - prevention &amp; control ; COVID-19 Vaccines - administration &amp; dosage ; COVID-19 Vaccines - adverse effects ; Drug-Related Side Effects and Adverse Reactions ; Female ; Health Personnel ; Hospitals, Teaching ; Humans ; Original ; Prospective Studies ; SARS-CoV-2 ; Universities ; Vaccines</subject><ispartof>Revista española de quimioterapia, 2023-08, Vol.36 (4), p.400-407</ispartof><rights>The Author 2023. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</rights><rights>The Author 2023 2023</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336310/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336310/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37119130$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Risco-Risco, C</creatorcontrib><creatorcontrib>Martínez-Urbistondo, D</creatorcontrib><creatorcontrib>Suárez Del Villar, R</creatorcontrib><creatorcontrib>Ayerbe García-Monzón, L</creatorcontrib><creatorcontrib>Pérez-Rubio, A</creatorcontrib><creatorcontrib>Barberán-López, J</creatorcontrib><creatorcontrib>Andaluz-Ojeda, D</creatorcontrib><creatorcontrib>Villares Fernández, P</creatorcontrib><title>Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)</title><title>Revista española de quimioterapia</title><addtitle>Rev Esp Quimioter</addtitle><description>Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs). Prospective post-authorization cohort study to monitor safety and effectiveness of the vaccine. Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic side effects were more frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 infection was associated with systemic effects after the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were reported. According to multivariate analysis, the degree of self-reported functional limitation after the first dose increased with age, female sex, previous COVID-19 contact, previous SARS-CoV-2 infection, and Charlson Comorbidity Index (CCI). After the second dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the degree of functional limitation after the first dose. Systemic adverse effects were more frequent after the second dose of Comirnaty. Previous SARS-CoV-2 infection was associated with systemic effects after the first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comirnaty®. After the 2nd dose, the degree of functional limitation was lower in those who previously had SARS-CoV-2 infection.</description><subject>BNT162 Vaccine</subject><subject>Cohort Studies</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention &amp; control</subject><subject>COVID-19 Vaccines - administration &amp; dosage</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Female</subject><subject>Health Personnel</subject><subject>Hospitals, Teaching</subject><subject>Humans</subject><subject>Original</subject><subject>Prospective Studies</subject><subject>SARS-CoV-2</subject><subject>Universities</subject><subject>Vaccines</subject><issn>0214-3429</issn><issn>1988-9518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc9u1DAQxi0EosvCkSvysRzS2p40sU-oivizUqUegF4t13Y2hsRObWfRvhS8A0-Gd1squMxoPD9938gfQq8pOYOWEXoe7d05oe0ZIwyeoBUVnFfigvKnaEUYrSuomThBL1L6RkgNtaDP0Qm0lAoKZIV-bXw_LtZri0OP7eyMnVwYw9ZpNWLlDdaj88ehVzqHmLDzOA8WR3uYt7YsXd7jHHAXJhe9yvvfP_FOae28PcCDVWMesFbR4h8hfrdFo3gp_HlW3qUBL97tyuNRpYgOzm_xENLscnE97a5vNjeXHU55Mfu3L9GzXo3Jvnroa_T1w_sv3afq6vrjpru8qjTUda4E4RQMNbUB1oIBoWlLoDGUsluua8WAa-BGgyhf2PRW0KbRBHpxIYD3BmCN3t3rzsvtZI22Pkc1yjm6ScW9DMrJ_zfeDXIbdpISgAZKXaPTB4UY7habspxc0nYclbdhSZJx0grKW2AFre5RHUNK0faPPpTIY8qypCxLyvKQcuHf_HvcI_03VvgD9SmnPw</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Risco-Risco, C</creator><creator>Martínez-Urbistondo, D</creator><creator>Suárez Del Villar, R</creator><creator>Ayerbe García-Monzón, L</creator><creator>Pérez-Rubio, A</creator><creator>Barberán-López, J</creator><creator>Andaluz-Ojeda, D</creator><creator>Villares Fernández, P</creator><general>Sociedad Española de Quimioterapia</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230801</creationdate><title>Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)</title><author>Risco-Risco, C ; Martínez-Urbistondo, D ; Suárez Del Villar, R ; Ayerbe García-Monzón, L ; Pérez-Rubio, A ; Barberán-López, J ; Andaluz-Ojeda, D ; Villares Fernández, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-90813d1d4d3273d39c17036d112b8c4a238c38dc392016fe9166c03f95938fd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>BNT162 Vaccine</topic><topic>Cohort Studies</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention &amp; control</topic><topic>COVID-19 Vaccines - administration &amp; dosage</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Female</topic><topic>Health Personnel</topic><topic>Hospitals, Teaching</topic><topic>Humans</topic><topic>Original</topic><topic>Prospective Studies</topic><topic>SARS-CoV-2</topic><topic>Universities</topic><topic>Vaccines</topic><toplevel>online_resources</toplevel><creatorcontrib>Risco-Risco, C</creatorcontrib><creatorcontrib>Martínez-Urbistondo, D</creatorcontrib><creatorcontrib>Suárez Del Villar, R</creatorcontrib><creatorcontrib>Ayerbe García-Monzón, L</creatorcontrib><creatorcontrib>Pérez-Rubio, A</creatorcontrib><creatorcontrib>Barberán-López, J</creatorcontrib><creatorcontrib>Andaluz-Ojeda, D</creatorcontrib><creatorcontrib>Villares Fernández, P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Revista española de quimioterapia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Risco-Risco, C</au><au>Martínez-Urbistondo, D</au><au>Suárez Del Villar, R</au><au>Ayerbe García-Monzón, L</au><au>Pérez-Rubio, A</au><au>Barberán-López, J</au><au>Andaluz-Ojeda, D</au><au>Villares Fernández, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)</atitle><jtitle>Revista española de quimioterapia</jtitle><addtitle>Rev Esp Quimioter</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>36</volume><issue>4</issue><spage>400</spage><epage>407</epage><pages>400-407</pages><issn>0214-3429</issn><eissn>1988-9518</eissn><abstract>Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs). Prospective post-authorization cohort study to monitor safety and effectiveness of the vaccine. Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic side effects were more frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 infection was associated with systemic effects after the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were reported. According to multivariate analysis, the degree of self-reported functional limitation after the first dose increased with age, female sex, previous COVID-19 contact, previous SARS-CoV-2 infection, and Charlson Comorbidity Index (CCI). After the second dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the degree of functional limitation after the first dose. Systemic adverse effects were more frequent after the second dose of Comirnaty. Previous SARS-CoV-2 infection was associated with systemic effects after the first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comirnaty®. After the 2nd dose, the degree of functional limitation was lower in those who previously had SARS-CoV-2 infection.</abstract><cop>Spain</cop><pub>Sociedad Española de Quimioterapia</pub><pmid>37119130</pmid><doi>10.37201/req/017.2023</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0214-3429
ispartof Revista española de quimioterapia, 2023-08, Vol.36 (4), p.400-407
issn 0214-3429
1988-9518
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10336310
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects BNT162 Vaccine
Cohort Studies
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - adverse effects
Drug-Related Side Effects and Adverse Reactions
Female
Health Personnel
Hospitals, Teaching
Humans
Original
Prospective Studies
SARS-CoV-2
Universities
Vaccines
title Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-09T06%3A32%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20epidemiological%20and%20clinical%20factors%20in%20the%20reactogenicity%20to%20Comirnaty%C2%AE%20vaccine%20in%20health%20care%20workers%20of%20a%20Spanish%20university%20teaching%20hospital%20(COVIVAC%20study)&rft.jtitle=Revista%20espa%C3%B1ola%20de%20quimioterapia&rft.au=Risco-Risco,%20C&rft.date=2023-08-01&rft.volume=36&rft.issue=4&rft.spage=400&rft.epage=407&rft.pages=400-407&rft.issn=0214-3429&rft.eissn=1988-9518&rft_id=info:doi/10.37201/req/017.2023&rft_dat=%3Cproquest_pubme%3E2807918732%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2807918732&rft_id=info:pmid/37119130&rfr_iscdi=true